• To date, ten priority transplant centers have been fully onboarded, five of whom have enrolled patients through the MyMesoblast™ hub. • Mesoblast anticipates onboarding an additional ten priority transplant centers in the current quarter. • The full team of nine key account managers (KAMs) commenced activities in the last week of April. The KAMs will accelerate onboarding of the remaining 35 priority transplant centers, accounting for 80% of U.S. pediatric transplants, and will drive the business to provide on the ground engagement with healthcare providers and administrators.
10 priority transplant centres onboarded with another 35 to go (assuming they all onboard whatever that means) to reach 80%. 10 this quarter. I'm happy with that I guess. Then the remaining 20% minor centres. I think progress is encouraging and hope as children are cured the word will spread and the snowball will continue rolling downhill building up mass and speed. Cash flow will surely follow.
There has been mention of the huge cash requirement to commercialise Rescovor (or whatever it's called). Can anyone explain how this works and the likely cost is? In any event commercialisation is a cost of generating cash flow.
Do agree the confusing numbers do little to assist analysis. With numbers so low at this stage more detailed data would be helpful.
Pipeline of new solutions is just awesome IMO. Looking to top up if SP wants to fall. Shorters need to be careful but must be cocky after latest run on the market.
MSB Price at posting:
$1.82 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)